CLINICAL_TRIALS
withdrawal
· 2013-06-21
Clinical Trial Update: Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis [Phase 2]
Summary
A Phase 2 proof-of-concept trial of BMS-823778 for atherosclerotic cardiovascular disease has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Atherosclerotic Cardiovascular Disease | Phase 2 | Status: WITHDRAWN